Multi Symptom Cold Relief tablets recalled for cGMP deviations
Ultra Seal Corporation is voluntarily recalling 673,160 packets of Multi Symptom Cold Relief tablets distributed nationwide due to cGMP (current Good Manufacturing Practice) deviations.
What this means for you
Minor labeling or packaging issue, or a voluntary precautionary recall. Risk of harm is low but real — follow the manufacturer's instructions.
Our severity reasoning: This is an FDA Class II recall initiated voluntarily for cGMP deviations. The source text contains no reports of actual illness, injury, or harm. Under the rubric, manufacturing deviations without reported adverse effects are classified as Moderate (score 2).
Plain-English summary
Ultra Seal Corporation is voluntarily recalling Multi Symptom Cold Relief tablets (containing acetaminophen 325 mg, Dextromethorphan HBr 15 mg, Guaifenesin 200 mg, and Phenylephrine HCl 5 mg) sold in 2-count packets and distributed by Honeywell Safety Products USA of Smithfield, Rhode Island. The recall affects 673,160 packets distributed nationwide within the United States.
The recall was initiated due to cGMP deviations discovered in the manufacturing process. The affected products are identified by Lot #AK9715 and K9715, with an expiration date of 07/2022.
Consumers who have purchased this product should stop using it. The recall was voluntarily initiated by the firm on January 24, 2022, and was classified as FDA Class II by the agency on January 31, 2022. The recall was terminated on October 16, 2023.
The recalled product
- Product
- Multi Symptom Cold Relief (acetaminophen 325 mg, Dextromethorphan HBr 15mg, Guaifenesin 200mg, Phenylephrine HCl 5mg) tablets, 2-count packets, Dist. by Honeywell Safety Products USA, Smithfield, RI 02917
- Manufacturer
- Ultra Seal Corporation
- Category
- Drug
- Hazard
- manufacturing-deviation
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (3)
- Lot #: AK9715
- K9715
- Exp. Date 07/2022
Distribution
Distributed nationwide across the United States.
Related recalls
Same category
- CriticalWarfarin Tablets Recalled After Mix-Up Between 2.5 mg and 5 mg Strengths
FDA (Drugs) · 2026-07-21
- ModerateFDA Recalls Pred Mild Ophthalmic Suspension Due to Failed Stability Specifications
FDA (Drugs) · 2026-06-03
- ModerateNicotine Transdermal System Patches Recalled for Oxidative Impurity Specification Failure
FDA (Drugs) · 2026-06-03
- HighLiraglutide Injection Recalled Due to Particulate Matter in Cartridges
FDA (Drugs) · 2026-05-27
- LowPrimidone Tablets Recalled for Cross-Contamination with Acemetacin
FDA (Drugs) · 2026-05-27